Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale

Thrombosis Research

Volumn 136, Issue 4, 2015, Pages 727-731

  Castellucci, Lana A ^a   Shaw, Joseph ^a   Van Der Salm, Katrien ^b   Erkens, Petra ^b,c   Le Gal, Gregoire ^a,d   Petrcich, William ^a   Carrier, Marc ^a,d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d INSTITUT DU SAVOIR MONTFORT   (Canada)

Author keywords

Anticoagulant; Medication adherence; Self report; Survey; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN;

ADULT; AGE DISTRIBUTION; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASSESSMENT OF HUMANS; CROSS-SECTIONAL STUDY; EMPLOYMENT STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MORISKY MEDICATION ADHERENCE SCALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; SECONDARY PREVENTION; SELF REPORT; SEX DIFFERENCE; ADOLESCENT; AGED; QUESTIONNAIRE; VENOUS THROMBOEMBOLISM; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SELF REPORT; SURVEYS AND QUESTIONNAIRES; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84941874998     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.07.007     Document Type: Article

References (29)

1. B. Brenner, and R. Hoffman Emerging options in the treatment of deep vein thrombosis and pulmonary embolism Blood Rev. 25 5 2011 215 221
2. A.T. Cohen, and M. Dobromirski The use of rivaroxaban for short- and long-term treatment of venous thromboembolism Thromb. Haemost. 107 6 2012 1035 1043
3. T. Vo, S. Vazquez, and M.T. Rondina Current state of anticoagulants to treat deep venous thrombosis Curr. Cardiol. Rep. 16 3 2014 463
4. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P.A. Reilly, E. Themeles, J. Varrone, S. Wang, M. Alings, D. Xavier, J. Zhu, R. Diaz, B.S. Lewis, H. Darius, H.C. Diener, C.D. Joyner, and L. Wallentin Dabigatran versus Warfarin in Patients with Atrial Fibrillation N. Engl. J. Med. 361 12 2009 1139 1151
5. S.J. Connolly, L. Wallentin, M.D. Ezekowitz, J. Eikelboom, J. Oldgren, P.A. Reilly, M. Brueckmann, J. Pogue, M. Alings, J.V. Amerena, A. Avezum, I. Baumgartner, A.J. Budaj, J.H. Chen, A.L. Dans, H. Darius, P.G. Di, J. Ferreira, G.C. Flaker, M.D. Flather, M.G. Franzosi, S.P. Golitsyn, D.A. Halon, H. Heidbuchel, S.H. Hohnloser, K. Huber, P. Jansky, G. Kamensky, M. Keltai, S.S. Kim, C.P. Lau, J.Y. Le Heuzey, B.S. Lewis, L. Liu, J. Nanas, R. Omar, P. Pais, K.E. Pedersen, L.S. Piegas, D. Raev, P.J. Smith, M. Talajic, R.S. Tan, S. Tanomsup, L. Toivonen, D. Vinereanu, D. Xavier, J. Zhu, S.Q. Wang, C.O. Duffy, E. Themeles, and S. Yusuf The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study Circulation 128 3 2013 237 243
6. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, G. Breithardt, J.L. Halperin, G.J. Hankey, J.P. Piccini, R.C. Becker, C.C. Nessel, J.F. Paolini, S.D. Berkowitz, K.A. Fox, and R.M. Califf Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation N. Engl. J. Med. 365 10 2011 883 891
7. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, H.R. Al-Khalidi, J. Ansell, D. Atar, A. Avezum, M.C. Bahit, R. Diaz, J.D. Easton, J.A. Ezekowitz, G. Flaker, D. Garcia, M. Geraldes, B.J. Gersh, S. Golitsyn, S. Goto, A.G. Hermosillo, S.H. Hohnloser, J. Horowitz, P. Mohan, P. Jansky, B.S. Lewis, J.L. Lopez-Sendon, P. Pais, A. Parkhomenko, F.W. Verheugt, J. Zhu, and L. Wallentin Apixaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 365 11 2011 981 992
8. Einstein Investigators, R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, H. Decousus, A.S. Gallus, A.W. Lensing, F. Misselwitz, M.H. Prins, G.E. Raskob, A. Segers, P. Verhamme, P.S. Wells, G. Agnelli, H. Bounameaux, A. Cohen, B.L. Davidson, F. Piovella, and S. Schellong Oral Rivaroxaban for Symptomatic Venous Thromboembolism N. Engl. J. Med. 363 26 2010 2499 2510
9. H.R. Buller, M.H. Prins, A.W. Lensin, H. Decousus, B.F. Jacobson, E. Minar, J. Chlumsky, P. Verhamme, P.S. Wells, G. Agnelli, A. Cohen, S.D. Berkowitz, H. Bounameaux, B.L. Davidson, F. Misselwitz, A.S. Gallus, G.E. Raskob, S. Schellong, and A. Segers Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N. Engl. J. Med. 366 14 2012 1287 1297
10. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, H. Eriksson, D. Baanstra, J. Schnee, and S.Z. Goldhaber Dabigatran versus warfarin in the treatment of acute venous thromboembolism N. Engl. J. Med. 361 24 2009 2342 2352
11. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, M. Johnson, U. Masiukiewicz, R. Pak, J. Thompson, G.E. Raskob, and J.I. Weitz Oral Apixaban for the Treatment of Acute Venous Thromboembolism N. Engl. J. Med. 369 9 2013 799 808
12. Health Canada Website http://www.hc-sc.gc.ca/ (Accessed February 28,2015)
13. European Medicine Agency Website http://www.ema.europa.eu/ema/ (Accessed February 28,2015).
14. U.S.Food and Drug Administration Website http://www.fda.gov/ (Accessed on February 28,2015)
15. R.A. Rodriguez, M. Carrier, and P.S. Wells Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? J. Thromb. Haemost. 11 2 2013 390 394
16. S. Schulman, and M.A. Crowther How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch Blood 119 13 2012 3016 3023
17. S. Schulman, B. Shortt, M. Robinson, and J.W. Eikelboom Adherence to anticoagulant treatment with dabigatran in a real-world setting J. Thromb. Haemost. 11 7 2013 1295 1299
18. J. Thachil The newer direct oral anticoagulants: a practical guide Clin. Med. 14 2 2014 165 175
19. S. Harder Renal profiles of anticoagulants J. Clin. Pharmacol. 52 7 2012 964 975
20. F. Rodriguez, C. Hong, Y. Chang, L.B. Oertel, D.E. Singer, A.R. Green, and L. Lopez Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic J. Am. Heart Assoc. 2 4 2013 e000170
21. D. Suryanarayan, and S. Schulman When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world-a problem or a myth? Semin. Thromb. Hemost. 40 8 2014 852 859
22. S. Schulman Advantages and limitations of the new anticoagulants J. Intern. Med. 275 1 2014 1 11
23. D.E. Morisky, L.W. Green, and D.M. Levine Concurrent and predictive validity of a self-reported measure of medication adherence Med. Care 24 1 1986 67 74
24. N.J. Davis, H.H. Billett, H.W. Cohen, and J.H. Arnsten Impact of adherence, knowledge, and quality of life on anticoagulation control Ann. Pharmacother. 39 4 2005 632 636
25. A.J. Claxton, J. Cramer, and C. Pierce A systematic review of the associations between dose regimens and medication compliance Clin. Ther. 23 8 2001 1296 1310
26. J.H. Arnsten, J.M. Gelfand, and D.E. Singer Determinants of compliance with anticoagulation: A case-control study Am. J. Med. 103 1 1997 11 17
27. A. Gorst-Rasmussen, F. Skjoth, T.B. Larsen, L.H. Rasmussen, G.Y. Lip, and D.A. Lane Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study J. Thromb. Haemost. 13 4 2015 495 504
28. P.Y. Lee, S.Y. Han, and R.K. Miyahara Adherence and outcomes of patients treated with dabigatran: pharmacist-managed anticoagulation clinic versus usual care Am. J. Health Syst. Pharm. 70 13 2013 1154 1161
29. S. Shore, E.P. Carey, M.P. Turakhia, C.A. Jackevicius, F. Cunningham, L. Pilote, S.M. Bradley, T.M. Maddox, G.K. Grunwald, A.E. Baron, J.S. Rumsfeld, P.D. Varosy, P.M. Schneider, L.N. Marzec, and P.M. Ho Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration Am. Heart J. 167 6 2014 810 817